Due to advances in cancer treatment the prognosis of which of the following has become better?
**Core Concept**
Advances in cancer treatment have led to improved prognosis for various malignancies. The key lies in understanding the specific tumor biology and the efficacy of targeted therapies.
**Why the Correct Answer is Right**
The prognosis of certain cancers has improved significantly due to the development of targeted therapies, such as tyrosine kinase inhibitors (TKIs) and checkpoint inhibitors. For instance, **Imatinib** has revolutionized the treatment of **Chronic Myeloid Leukemia (CML)** and **Gastrointestinal Stromal Tumor (GIST)** by specifically inhibiting BCR-ABL and KIT/ PDGFR tyrosine kinases, respectively. Similarly, **Immunotherapies**, including **PD-1/PD-L1 inhibitors**, have shown remarkable efficacy in treating **Non-Small Cell Lung Cancer (NSCLC)** and **Melanoma** by enhancing the body's immune response against cancer cells.
**Why Each Wrong Option is Incorrect**
**Option A:** While the prognosis of certain cancers has improved, the overall 5-year survival rate for **Breast Cancer** has not significantly changed in recent years due to the development of resistance to targeted therapies.
**Option B:** The prognosis of **Pancreatic Cancer** remains poor, despite advances in cancer treatment, due to its aggressive biology and late diagnosis.
**Option C:** The prognosis of **Hepatocellular Carcinoma (HCC)** has not significantly improved with current treatments, and new therapeutic strategies are being explored to improve patient outcomes.
**Clinical Pearl / High-Yield Fact**
When considering the prognosis of cancer patients, it's essential to remember that the **tumor biology** and **response to targeted therapies** play a crucial role in determining patient outcomes.
**Correct Answer:** C.